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Five mouse ascitic fluids (MAFs) containing monoclonal antibody to Rickeutsia ricketsii were produced from
three original fusions by murine hybridoma technology. The five MAFs were fractionated and purified; each
contained monoclonal antibody of the immunoglobulin G2a subclass. Each monoclonal antibody-containing
MAF was titrated by indirect immunofluorescence against three R. ricketsii isolates from humans and four
other spotted fever group rickettsiae. Each MAF was also titrated in the complement fixation, latex
agglutination, microagglutination, and indirect hemagglutination tests. Two of the MAFs were examined for
their ability to prevent fever and rickettsemia in susceptible guinea pigs after a 1:100 dilution of each was mixed
with viable R. rickettsii, and all five MAFs were titrated in the mouse toxicity phenomenon assay. All MAFs had
high indirect immunofluorescence titers to the three strains of R. rickettsii (1:200,000 to 1:800,000), reduced
indirect immunofluorescence titers to R. montana, and were nonreactive with R. akari, R. sibirica, and R.
conorii. Each MAF was able to fix complement in the presence of spotted fever group antigen reagent and
agglutinate a suspension of purified R. rickettsii, and each was negative in both the latex agglutination and the
indirect hemagglutination tests. The two MAFs which were tested proved to be capable of preventing
rickettsemia and death in guinea pigs, and each MAF was able to prevent death in mice at dilutions ranging
from 1:40 to 1:80.
Rickettsia rickettsii, the etiological agent of Rocky Moun-
tain spotted fever, continues to be a major cause of human
morbidity and mortality in the continental United States (5).
A detailed knowledge of the biochemical structure of R.
rickettsii, its antigenic constituents, and whether there is
strain variation at the structural subunit level, are questions
which remain unresolved.
Murine hybridoma technology has provided a powerful
tool for obtaining useful information on the immunochemical
makeup of complex organisms. Monoclonal antibodies have
been used to identify surface proteins on Pseudomonas
aeruginosa (18), to differentiate strains of Bacteroides inter-
medius (12), to identify and classify microorganisms (6), and
to purify a relevant antigen from Babesia bovis (25).
To our knowledge, monoclonal antibodies to spotted fever
group (SFG) rickettsiae have not been described. To investi-
gate the relationship among strains of R. rickettsii and
between R. rickettsii and other SFG organisms, we have
produced monoclonal antibodies against R. rickettsii. This
paper describes how these antibodies were produced and
how they were characterized by various serological and
biological methods.
MATERIALS AND METHODS
Rickettsiae. The Sheila Smith (SS) strain of R. rickettsii
was passed an undetermined number of times in guinea pigs
and embryonated hen eggs and three times in L-929 mouse
fibroblasts before its use as a live, whole immunogen.
Clinical isolates were obtained in L-929 mouse and RK-13
rabbit kidney cells as previously described (14, 17). Rickett-
siae were propagated in various cell lines for preparing stock
pools and fluorescent antigen (Table 1).
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Fluorescent antigen. A portion of each rickettsia-host
suspension was centrifuged at 5,000 x g for 30 min. The
pellet was suspended in 5 ml of phosphate-buffered saline
(0.1 M Na2HPO4 [anhydrous], 0.1 M NaH2PO4, 0.15 M
NaCl, [pH 7.2 to 7.4]). The suspension was applied to 2 wells
of a 12-well Teflon-coated slide and examined under a
standard light microscope. The suspension was diluted with
phosphate-buffered saline until 1 drop contained well dis-
persed cells. The diluted suspension was then dispensed
onto 12-well slides, allowed to air dry, acetone fixed for 10
min at room temperature, checked for the presence of SFG
rickettsiae by a direct immunofluorescent system, and
stored at -70°C.
Quantitation of rickettsiae. Rickettsiae were quantitated in
cell culture as previously described (14).
Culture ceils. A passage of Sp2/0-Agl4 (23) plasmacytoma
cells was obtained from Howard M. Reisner, Department of
Pathology, University of North Carolina-Chapel Hill School
of Medicine, and cultured in antibiotic-free RPMI 1640
medium (GIBCO Laboratories, Grand Island, N.Y.) supple-
mented with 15% heat-inactivated (at 56°C for 60 min) fetal
bovine serum (Sterile Systems, Inc., Logan, Utah) and
containing 8-azaguanine (Sigma Chemical Co., St. Louis,
Mo.). Selective medium consisted of RPMI 1640 medium
with 15% fetal bovine serum which contained hypoxanthine
and aminopterin as described by Oi and Herzenberg (19).
Immunization of mice. Six- to eight-week-old BALB/c
mice (Charles River Breeding Laboratories, Inc., Wilming-
ton, Mass.) were injected intravenously with a 2 x 106 50%
tissue-culture-infective dose of R. rickettsii SS from an
aliquoted pool in brain heart infusion (BHI) broth (Difco
Laboratories, Detroit, Mich.). Three weeks later, mice re-
ceived a 3.1 x 106 50% tissue-culture-infective dose of R.
rickettsii SS from the original pool.
Fusion and cloning. Spleen cells from two mice were
pooled and fused with SP2/0-Agl4 myeloma cells (1:1) by
using polyethylene glycol 1500 (Sigma) as the fusing agent
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(19). After incubation for 18 h at 36°C in an atmosphere of
4% CO2 and 65 to 75% relative humidity, 0.1 ml of selective
medium was added to each well. Selective medium was
changed at 72-h intervals thereafter. The supernatants of
wells with viable growth were screened for immunoglobulin
M (IgM) and IgG antibodies to R. rickettsii by the indirect
fluorescent antibody (IFA) assay (8, 21). Cells from anti-
body-positive wells were expanded, cryopreserved, cloned,
and recloned by limiting dilution (19) in low-serum medium
with 4% fetal bovine serum (Hybridoma Sciences, Inc.,
Atlanta, Ga.).
Ascites production. BALB/c mice were injected intraperi-
toneally with 500 mg of Pristane (0.5 ml; Aldrich Chemical
Co., Inc., Milwaukee, Wisc.) 4 to 6 weeks before intraperito-
neal injection of 3 to 5 x 106 cloned cells in low-serum
medium without fetal bovine serum. Mouse ascites fluid
(MAF) was collected from days 10 through 30 after cell
injection and defibrinated with 2 M glacial acetic acid (11),
and the globulin fraction was precipitated with (NH4)2SO4 to
50% saturation.
Isotype determination. Each MAF fraction was purified on
a protein-A-agarose (E-Y Laboratories, San Mateo, Calif.)
column (22). The column was equilibrated with 0.1 M
Na2HPO4 adjusted to pH 8.2 with 0.1 M citrate (starting
buffer). The sample was dialyzed into starting buffer, applied
to the column, and 2- 3-ml fractions were collected. The
column was eluted with starting buffer until the first peak
appeared, and then a pH gradient was run with 30 ml each of
starting buffer and citrate buffer in a gradient mixer. After
the gradient was completed, the pH of each fraction was
determined and then adjusted to 7.0 to 7.5 with 1 M Tris-
hydrochloride, pH 8.5. Each fraction was tested for antibody
to R. rickettsii in the IFA assay, and each was examined in
an Ouchterlony gel against rabbit antiserum (Miles Labora-
tories, Inc., Elkhart, Ind.) specific for each of the respective
mouse IgG subclasses.
Serological characterizations. Each MAF sample was ti-
trated in the IFA assay and in the complement fixation (CF)
(4), microagglutination (MA) (10), latex agglutination (LA)
(13), and indirect hemagglutination (IHA) (20) tests.
Biological characterization. Randomly bred male Hartley




R. rickettsii SS......... L-929
R. rickettsii LNC.................. L-929
RK-13
R. rickettsii DDH .................. L-929
R. akari Kaplan .................... CE
R. sibirica ATCC-VR-151 ................... CE
E-6
R. conorii Str 7 .................. L-929
E-6
R. montana ATCC-VR-611 ................... L-929
E-6
TABLE 2. Reciprocal IFA titers of monoclones to SFG
rickettsiae
Titer of MAF fractionate:
Antigen Ell- Ell- E12- Ell- Ell-
1G8 2F1 2H11 1G2 1F12
R. rickettsii SS 600,000 400,000 200,000 400,000 800,000
R. rickettsii LNC 200,000 200,000 100,000 200,000 100,000
R. rickettsii DDH 600,000 400,000 100,000 200,000 600,000
R. montana 320 320 40 640 640
ATCC VR611
R. akari Kaplan <8 <8 <8 <8 <8
R. sibirica <8 <8 <8 <8 <8
ATCC VR151
R. conorii Str 7 <8 <8 <8 <8 <8
strain guinea pigs 8 to 12 weeks old and ICR/Swiss Webster
white mice were obtained from the Animal Resources
Branch, Centers for Disease Control, Atlanta, Ga. Two
monoclonal antibody-containing MAF samples were tested
for their ability to protect guinea pigs from fever and
rickettsemia (1). Portions of the eighth L-929 passage of R.
rickettsii SS were mixed with immune MAF, control MAF,
or buffer, and incubated at room temperature for 1 h; 1.0 ml
per animal was injected intraperitoneally into groups of six
guinea pigs for each mixture (see below). Each MAF was
diluted 1:100 in buffer, and this 1:100 dilution was used to
react with the rickettsiae. The tissue culture infectivity of
each mixture was determined after the 1-h incubation. Rectal
temperatures were recorded daily, and animals were bled by
cardiac puncture on day 1 after injection and every other day
thereafter through day 18. Serum was separated by centrifu-
gation (800 x g), and portions were stored in liquid nitrogen
vapor until titration in L-929 cells for rickettsiae and by the
IFA assay for antibody.
Dilutions of each MAF fractionate in BHI broth, control
MAF, and BHI were mixed 1:1 with a pool of R. rickettsii
SS. the mixtures were incubated for 1 h at room temperature
and then injected intravenously in 0.3-ml volumes into mice
(3). Mice were observed for the occurrence of toxic death for
18 h after injection (3).
RESULTS
After 5 weeks in selective medium, 17 of the 576 original
cultures contained IgG antibodies to R. rickettsii only. Nine
of the expanded hybrids continued to produce antibody.
Three of these were cloned, and six cultures from the first
cloning were recloned. Six of the subclones were used for
injection into mice after expansion and cryopreservation.
Five of the six groups of mice produced ascites, with the
pooled MAF samples of each group having an IFA titer to R.
rickettsii SS of >1:16,384.
The 50% ammonium sulfate fractionate of each MAF pool
was purified on a protein-A agarose column under a pH
gradient. Fractions which fell under the second peak were
the only fractions which contained antibody to R. rickettsii.
In the Ouchterlony gels, the fractions under the second peak
formed a line of identity with the anti-IgG2a antiserum only.
The unpurified MAF fractionate formed precipitin lines in
the gels with anti-IgGl and IgG3.
IFA titers of the MAF fractionates to R. rickettsii SS
ranged from 1:200,000 to 1:800,000 (Table 2). The titers
against two other strains of R. rickettsii (LNC and DDH) (14,
17) were within a threefold range of the homologous strain
(SS) titer, with one exception. The titer of MAF E11-1F12
versus the R. rickettsii LNC human isolate was consistently
a L-929, mouse fibroblasts; RK-13, rabbit kidney; CE, primary chicken
embryo; E-6, African green monkey kidney (clone E-6).
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TABLE 3. Reciprocal titers of MAF globulin fractions to R.
rickettsii in CF, MA, LA, and IHA testsa
Titer of MAF fractionate
Test
E11-lG8 E11-2F1 E12-3H11 E11-lG2 E1l-lF12
CF 256 256 64 256 128
MA 64 64 16 64 64
LA <8 <8 <8 <8 <8
IHA <16 <16 <16 <16 <16
a Controls titers: CF (guinea pig), 128 (immune) <8 (normal); MA (guinea
pig), 32 (immune); <4 (normal); LA (human), 64 (immune), <8 (normal); IHA
(human), 128 (immune), <16 (normal).
one-eighth that of its titer with SS. Table 2 also presents
titration data on each MAF fractionate against other SFG
rickettsiae in the IFA assay. No MAF sample was reactive
with Rickettsia akari, R. sibirica, or R. conorii. Each MAF
sample did react with R. montana, although at significantly
lower titers (1:40 to 1:640) than those obtained with R.
rickettsii.
None of the rickettsiae could be differentiated on a qualita-
tive basis in the IFA assay. The staining pattern was a
completely circumferential rim fluorescence for each posi-
tive rickettsia. Quantitatively, R. rickettsii could be easily
differentiated from any of the other SFG rickettsiae.
The data from titrations of each monoclone in the CF,
MA, LA, and IHA tests are shown in Table 3. Each
monoclone was able to fix complement in the presence of
SFG antigen in the CF test. Titers ranged from 1:64 to 1:256.
The MA results indicate that each monoclone will aggluti-
nate a purified suspension of R. rickettsii at relatively low
titers (1:16 to 1:64). None of the monoclones was reactive in
either the LA or the IHA tests. Both of these tests rely on
reactivity with the so-called erythrocyte-sensitizing sub-
stances.
The two monoclones which were tested proved to be
capable of preventing rickettsemia and death, and they also
prevented fever in five of six guinea pigs which received
mixtures of viable R. rickettsii and each of the respective
monoclones (Figs. 1 and 2).
After an incubation period of 1 h at room temperature,
each of the mixtures contained tissue-culture-infective rick-
ettsiae. The mixtures of Snyder I buffer, control (Lassa)
MAF, MAF E11-1G8, and MAF E11-2F1 with rickettsiae
contained 1054, 104-5, 103.0, and 1025 50% tissue-culture-
infective dose per ml of tissue-culture-infective rickettsiae,
respectively.
All of the animals which received buffer or control MAF-
rickettsiae mixtures became febrile (>39.70C) (Fig. 1). Fever
in the buffer-rickettsiae group began on day 5 and persisted
through day 10, with deaths occurring on days 5, 6, 9, 10,
and 12. A febrile reaction began on day 4 and lasted through
day 9 in the control MAF-rickettsiae group, with deaths on
days 9, 10, and 12. All animals in these two groups were
anorectic on day 6 and had bilateral hemorrhagic necrosis of
the scrotum on day 8. By day 13 after challenge, only one
animal remained alive in each of these groups.
One animal in each of the E11-lG8 and E11-2F1 groups
became febrile (Fig. 1). The animal in the E11-lG8-rickettsi-
ae group had a fever of 40.0°C on day 9, 40.2°C on day 10,
and was afebrile thereafter. The E11-2F1-rickettsiae group
febrile reactor reached 39.7°C on day 8 and defervesced by
day 9. Controls injected with each respective MAF or buffer
were afebrile throughout the experiment.
Levels of rickettsemia in each group are presented in Fig.
2. Rickettsiae were isolated from the blood of every animal
in both the buffer and control MAF-rickettsiae groups. Low
levels of rickettsemia (100.7 to 101.2) were present on day 5
after infection. Rickettsemia peaked on day 7 in the buffer-
rickettsiae group and on day 9 in the control MAF-rickettsi-
ae group. Rickettsemia dropped to undetectable levels in the
survivor of each group by day 14. No animal in either group
which received immune MAF-rickettsiae had detectable
rickettsemia through day 13.
The mean reciprocal IFA titers of each group of animals
are shown in Fig. 3. Antibody was detectable as early as day
7 and peaked on day 24. All animals that received rickettsiae
in any of the mixtures responded immunologically.
The mouse toxicity phenomenon (3) neutralization results
are presented in Table 4. Each MAF was able to prevent
death in all mice at dilutions which varied from 1:40 (Eli-
lHil) to 1:80 (E11-lF12). Clear-cut endpoints were obtained
with two MAFs, whereas the other three partially protected
against the MTP at dilutions greater than their optima. In the
control groups, all BHI-rickettsiae recipients, and 10 of 14
control MAF-rickettsiae recipients died.
DISCUSSION
We have shown that monoclonal antibodies to a complex
organism such as R. rickettsii can be produced by murine
hybrid cell technology. A total of six monoclones were
obtained after fusion and two clonings. Each monoclone was
of the IgG class and IgG2a subclass. The 50% (NH4)2SO4
fractionates ofMAF of five of the monoclones had very high
IFA titers to the homologous (SS) strain of R. rickettsii
(Table 2). IFA titers of each MAF fractionate to two other
strains of R. rickettsii (LNC and DDH) were within a two- to
threefold range of the homologous titer with one exception.
MAF E11-lF12 had a titer to the LNC strain which was one-
eighth that of the homologous strain titer and one-sixth that
obtained with the DDH strain. Whether the LNC strain
possesses relatively less of a particular epitope which MAF







2 34 5 e 7 8 1101112 13 14 1 16 17 18
Days After ChaNeng.
FIG. 1. Mean temperatures of guinea pigs inoculated with mix-
tures of R. rickettsii and monoclone E11-lG8 (0), monoclone Ell-
2F1 (0), Lassa MAF 52.93.4 (U), and buffer (C1). No. D, Number
dead; no./no., febrile/afebrile; *, hypothermic (<37.0°C).
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FIG. 2. Rickettsemia in guinea pigs inoculated with mixtures of R. rickettsii and monoclone E11-lG8 (0), monoclone E11-2F1 (0), Lassa
MAF 52.93.4 (A), and buffer (O). -1, <1; no. D, number dead.
protein profile of the LNC isolate with those of the other
strains of R. rickettsii. On a qualitative basis, all three strains
of R. rickettsii were identical. Quantitatively, four of the five
monoclones could not differentiate any of the strains of R.
rickettsii. In a study which used polyclonal mouse antisera
to compare human isolates of R. rickettsii from patients in
North Carolina and Montana, Davis et al. (7) found no
differences among any of the 12 strains which were exam-
ined. This limited serological evidence does not support the
concept that strain variation might account for the spectrum
of disease severity which is seen in Rocky Mountain spotted
fever.
None of the monoclones was cross-reactive with three
other species of SFG rickettsiae which cause human disease.
R. akari, R. sibirica, and R. conorii did not react with any of
the monoclones in the IFA assay, although each was reac-
tive with a group-specific polyclonal antiserum. Thus, any of
these monoclones can be used to distinguish R. rickettsii
from any of the above rickettsiae.
All monoclones did react with R. montana, although at
significantly lower titers than with any strain of R. rickettsii.
These data indicate that R. rickettsii and R. montana share
an epitope that is recognized by these monoclonal antibodies
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FIG. 3. Mean reciprocal IFA titers of guinea pig sera from animals inoculated with mixtures of R. rickettsii and monoclone E11-1G8 (0),
monoclone E11-2F1 (0), Lassa MAF 52.93.4 (-), and buffer (O). -1: <4.
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TABLE 4. Neutralization of toxic death in mice by monoclonal
antibodies to R. rickettsii
MAF Dilution'a No. No. Titerinjected surviving
Ell-lG8 1:100 3 0
1:80 3 2
1:50 3 3 1:50
1:40 3 3
1:20 3 3
E11-2F1 1:100 3 0
1:80 3 0
1:50 3 3 1:50
1:40 3 3
1:20 3 3
Ell-lG2 1:100 3 0
1:80 3 1
1:50 3 1 1:40
1:40 3 3
1:20 3 3
Ell-ilHl 1:100 3 0
1:80 3 0
1:50 3 1 1:40
1:40 3 3
1:20 3 3
Ell-1F12 1:100 3 0
1:80 3 3




52.93'4 1:20 14 4
BHI alone 10 10
MAFs alone 1:20 12 12
a Final dilution after mixing 1:1 with rickettsiae.
this epitope. In a serological analysis of polyclonal rabbit
antibody against a purified surface component of R. rickett-
sii, Anacker et al. (1) demonstrated cross-reactivity between
R. montana, R. conorii, R. sibirica, and the R. ricketsii-
component antibody, with R. akari being nonreactive. The
polyclonal antiserum of Anacker et al. and the monoclones
in the present study probably recognize different epitopes,
neither of which is present on R. akari. In a cross-protection
study in guinea pigs, Feng and Waner (9) reported that the
nonpathogenic R. montana protected animals from death
when challenged with R. rickettsii.
Further serological characterization of each monoclone
indicates that each will fix complement in the presence of the
group CF antigen reagent, a complex mixture containing at
least four major proteins (24), and moreover, that each will
agglutinate a purified suspension of R. rickettsii. Considered
together, the MA, IHA, and LA results provide indirect
evidence that the monoclones are directed to some surface
component other than the slime layer since both the LA and
IHA tests use the carbohydrate erythrocyte-sensitizing sub-
stance as their antigen (20) and the erythrocyte-sensitizing
substance has never been shown on purified organisms.
The biological characterization data indicate that the two
monoclones which were tested can prevent rickettsemia and
death in guinea pigs and can also reduce the severity and
length of fever in animals which do become febrile. Although
tissue-culture-infective rickettsiae remained in the mono-
clone-rickettsiae mixtures, the organisms were not able to
proliferate to detectable levels (Fig. 2). This is probably due
to opsonization, as shown in vitro with guinea pig leukocytes
and antibody-coated and uncoated rickettsiae (15). Howev-
er, the organisms in the mixture were able to persist at or
proliferate to levels which were immunogenic (Fig. 3). At
higher concentrations of antibody (<1:100), it might be
possible to eliminate all tissue-culture-infective rickettsiae.
Each monoclone proved to be capable of preventing the
mouse toxicity phenomenon. These data, along with the
guinea pig data, suggest that the antigen(s) on viable R.
rickettsii which are recognized may be involved in some
step(s) in the pathogenic mechanism. This would probably
involve either an attachment or penetration mechanism on
the part of the organism. The fact that the number of tissue-
culture-infective rickettsiae in the monoclone-rickettsiae
mixtures was significantly less than that of the controls
suggests that inactivation did take place. Although agglutina-
tion may have accounted for the reduction, the dilution of
each monoclone (1:100) was greater than its maximum LA
titer. This contrasts with the data of Kenyon and McManus
(16), who showed that virtually all complexes of R. rickettsii
and rhesus anti-R. rickettsii antibody were infectious for
chicken embryo cultures unless the complexes were treated
with an antirhesus immunoglobulin.
A proper dilution of each monoclone will clearly differen-
tiate R. rickettsii from any of the other SFG organisms which
were examined in the IFA assay. When tested against other
SFG rickettsiae, they may prove to be useful in differentiat-
ing R. rickettsii from any of the other members of the group.
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